JaLCDOI 10.18926/AMO/64363
フルテキストURL 77_1_65.pdf
著者 Sato, Ken| Takigawa, Nagio| Kubo, Toshio| Katayama, Hideki| Kishino, Daizo| Okada, Toshiaki| Hisamoto, Akiko| Mimoto, Junko| Ochi, Nobuaki| Yoshino, Tadashi| Ueoka, Hiroshi| Tanimoto, Mitsune| Maeda, Yoshionobu| Kiura, Katsuyuki|
抄録 We investigated the effects of celecoxib combined with (−)-epigallocatechin-3-gallate (EGCG) or polyphenon E in a cisplatin-induced lung tumorigenesis model. Four-week-old female A/J mice were divided into seven groups: (i) Control, (ii) 150 mg/kg celecoxib (150Cel), (iii) 1,500 mg/kg celecoxib (1500Cel), (iv) EGCG+150 mg/kg celecoxib (EGCG+150Cel), (v) EGCG+1,500 mg/kg celecoxib (EGCG+1500Cel), (vi) polyphenon E+150 mg/kg celecoxib (PolyE+150Cel), and (vii) polyphenon E+1,500 mg/kg celecoxib (PolyE+1500Cel). All mice were administered cisplatin (1.62 mg/kg of body weight, i.p.) 1×/week for 10 weeks and sacrificed at week 30; the numbers of tumors on the lung surface were then determined. The tumor incidence and multiplicity (no. of tumors/mouse, mean±SD) were respectively 95% and 2.15±1.50 in Control, 95% and 2.10±1.29 in 150Cel, 86% and 1.67±1.20 in 1500Cel, 71% and 1.38±1.24 in EGCG+150Cel, 67% and 1.29±1.38 in EGCG+1500Cel, 80% and 1.95±1.36 in PolyE+150Cel, and 65% and 1.05±0.10 in PolyE+1500Cel. The combination of high-dose celecoxib with EGCG or polyphenon E significantly reduced multiplicity in cisplatin-induced lung tumors.
キーワード celecoxib cisplatin EGCG lung tumor polyphenon E
Amo Type Original Article
出版物タイトル Acta Medica Okayama
発行日 2023-02
77巻
1号
出版者 Okayama University Medical School
開始ページ 65
終了ページ 70
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
著作権者 Copyright Ⓒ 2023 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 36849147
Web of Science KeyUT 000952992100004
JaLCDOI 10.18926/AMO/55446
フルテキストURL 71_5_453.pdf
著者 Taniguchi, Akihiko| Miyahara, Nobuaki| Oda, Naohiro| Morichika, Daisuke| Ichihara, Eiki| Oze, Isao| Tanimoto, Yasushi| Ichikawa, Hirohisa| Fujii, Utako| Tanimoto, Mitsune| Kanehiro, Arihiko| Kiura, Katsuyuki|
抄録 Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.
キーワード chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure
Amo Type Clinical Study Protocol
出版物タイトル Acta Medica Okayama
発行日 2017-10
71巻
5号
出版者 Okayama University Medical School
開始ページ 453
終了ページ 457
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
著作権者 CopyrightⒸ 2017 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29042706
著者 後藤田 達洋| 川野 誠司| 河野 吉泰| 三浦 公| 神崎 洋光| 岩室 雅也| 河原 祥朗| 田中 健大| 吉野 正| 白川 靖博| 田端 雅弘| 谷本 光音| 岡田 裕之|
発行日 2016-12-01
出版物タイトル 岡山医学会雑誌
128巻
3号
資料タイプ 学術雑誌論文
著者 谷本 光音|
発行日 2016-12-01
出版物タイトル 岡山医学会雑誌
128巻
3号
資料タイプ 一般雑誌記事
JaLCDOI 10.18926/AMO/54603
フルテキストURL 70_5_409.pdf
著者 Maeda, Yoshinobu| Nishimori, Hisakazu| Inamoto, Yoshihiro| Nakamae, Hirohisa| Sawa, Masashi| Mori, Yasuo| Ohashi, Kazuteru| Fujiwara, Shin-ichiro| Tanimoto, Mitsune|
抄録 Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.
キーワード Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD
Amo Type Clinical Study Protocols
出版物タイトル Acta Medica Okayama
発行日 2016-10
70巻
5号
出版者 Okayama University Medical School
開始ページ 409
終了ページ 412
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27777437
Web of Science KeyUT 000388098700014
JaLCDOI 10.18926/AMO/54608
フルテキストURL 70_5_429.pdf
著者 Asano, Takeru| Matsuoka, Ken-ichi| Iyama, Satoshi| Ohashi, Kazuteru| Inamoto, Yoshihiro| Ohwada, Chikako| Murata, Makoto| Satake, Atsushi| Yoshida, Chikamasa| Nakase, Koichi| Mori, Yasuo| Tanimoto, Mitsune|
抄録 Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT.
キーワード chronic GVHD allogeneic HSCT steroid refractory IL-2
Amo Type Clinical Study Protocols
出版物タイトル Acta Medica Okayama
発行日 2016-10
70巻
5号
出版者 Okayama University Medical School
開始ページ 429
終了ページ 433
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27777442
Web of Science KeyUT 000388098700019
JaLCDOI 10.18926/AMO/54503
フルテキストURL 70_4_273.pdf
著者 Makimoto, Go| Miyahara, Nobuaki| Yoshikawa, Mao| Taniguchi, Akihiko| Kanehiro, Arihiko| Tanimoto, Mitsune| Kiura, Katsuyuki|
抄録 Heerfordtʼs syndrome is a rare manifestation of sarcoidosis and is defined as a combination of facial palsy, parotid swelling, and uveitis, associated with a low-grade fever. We report a case of Heerfordtʼs syndrome presenting with a high fever and increased serum tumor necrosis factor alpha (TNF-α) levels. The patient had facial palsy, parotid swelling, uveitis, and swelling of the right supraclavicular and hilar lymph nodes. Corticosteroid therapy was initiated, and her symptoms soon resolved completely, in tandem with a decrease in TNF-α serum levels.
キーワード Heerfordtʼs syndrome sarcoidosis TNF-α
Amo Type Case Report
出版物タイトル Acta Medica Okayama
発行日 2016-08
70巻
4号
出版者 Okayama University Medical School
開始ページ 273
終了ページ 277
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27549672
Web of Science KeyUT 000384748600007
JaLCDOI 10.18926/AMO/54499
フルテキストURL 70_4_243.pdf
著者 Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki|
抄録 Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p<0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation.
キーワード vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse
Amo Type Original Article
出版物タイトル Acta Medica Okayama
発行日 2016-08
70巻
4号
出版者 Okayama University Medical School
開始ページ 243
終了ページ 253
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27549668
Web of Science KeyUT 000384748600003
タイトル(別表記) The 55th Annual Meeting of the Japanese Society for Lymphoreticular Tissue Research
フルテキストURL 128_67.pdf
著者 谷本 光音|
出版物タイトル 岡山医学会雑誌
発行日 2016-04-01
128巻
1号
開始ページ 67
終了ページ 68
ISSN 0030-1558
関連URL isVersionOf https://doi.org/10.4044/joma.128.67
言語 日本語
著作権者 Copyright (c) 2016 岡山医学会
論文のバージョン publisher
DOI 10.4044/joma.128.67
NAID 130005149608
JaLCDOI 10.18926/AMO/53671
フルテキストURL 69_5_261.pdf
著者 Nojima, Daisuke| Fujimoto, Nobukazu| Kato, Katsuya| Fuchimoto, Yasuko| Kiura, Katsuyuki| Kishimoto, Takumi| Tanimoto, Mitsune|
抄録 We investigated the clinical features of asbestos-induced diffuse pleural thickening (DPT) with severe respiratory compromise. We conducted a retrospective study of consecutive subjects with asbestos-induced DPT. Medical data such as initial symptoms, radiological findings, respiratory function test results, and clinical course were collected and analyzed. There were 24 patients between 2003 and 2012. All were men, and the median age at the development of DPT was 74 years. The top occupational category associated with asbestos exposure was dockyard workers. The median duration of asbestos exposure was 35.0 years, and the median latency from first exposure to the onset of DPT was 49.0 years. There were no significant differences in respiratory function test results between the higher and lower Brinkman index groups or between unilateral and bilateral DPT. Thirteen patients had a history of benign asbestos pleural effusion (BAPE), and the median duration from pleural fluid accumulation to DPT with severe respiratory compromise was 28.4 months. DPT with severe respiratory compromise can develop after a long latency following occupational asbestos exposure and a history of BAPE.
キーワード asbestos pleural thickening MRC dyspnea scale respiratory function test costophrenic angle
Amo Type Original Article
出版物タイトル Acta Medica Okayama
発行日 2015-10
69巻
5号
出版者 Okayama University Medical School
開始ページ 261
終了ページ 266
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26490022
Web of Science KeyUT 000365519600001
JaLCDOI 10.18926/AMO/53025
フルテキストURL 68_6_363.pdf
著者 Ota, Seisuke| Hiramatsu, Yasushi| Kondo, Eisei| Kasahara, Akinori| Takada, Saimon| Umena, Sachio| Noguchi, Toshio| Tanimoto, Mitsune| Matsumura, Tadashi|
抄録 Leukocytosis is occasionally seen in patients with presumptive but undiagnosed myeloproliferative disorders (MPD). A 74-year-old woman was admitted to our hospital for tarry stools, anemia, and marked peripheral leukocytosis of 1.4×105/μL. Gastroenteroscopy revealed an acute gastric and duodenal mucosal lesion that was treated successfully via endoscopic hemoclipping. Bone marrow aspiration revealed marked megakaryocyte proliferation with atypia of naked nuclei and marrow hypercellularity (90% cellularity). A fluorescence in situ hybridization test could not detect the BCR-ABL fusion gene. Bone marrow aspiration later revealed further abnormalities of megakaryocytes. The patient died from cerebral bleeding. The present case fulfilled 2 of the 3 major criteria of primary myelofibrosis according to the World Health Organization 2008 classification:namely, megakaryocytic hyperplasia with hypercellular marrow and granulocytic hyperplasia. However, the megakaryocytic abnormality was not strictly compatible with the criteria. Instead, we considered prefibrotic primary myelofibrosis as a possibility, although myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) was technically the correct diagnosis. The present case shows that MPN diagnosis remains difficult and suggests that other cases of peripheral leukocytosis with diagnosed MDS/MPN-U might include similar findings.
キーワード prefibrotic primary myelofibrosis leukocytosis anemia acute gastric mucosal lesion multiple cerebral hemorrhages
Amo Type Case Report
出版物タイトル Acta Medica Okayama
発行日 2014-12
68巻
6号
出版者 Okayama University Medical School
開始ページ 363
終了ページ 368
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 英語
著作権者 CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 25519030
Web of Science KeyUT 000346882200006
著者 Yasugi, Masayuki| Takigawa, Nagio| Ochi, Nobuaki| Ohashi, Kadoaki| Harada, Daijiro| Ninomiya, Takashi| Murakami, Toshi| Honda, Yoshihiro| Ichihara, Eiki| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2014-08-15
出版物タイトル Experimental Cell Research
326巻
2号
資料タイプ 学術雑誌論文
タイトル(別表記) Treatment for a non-compliant patient with cancer and epilepsy
フルテキストURL 126_133.pdf
著者 南 大輔| 市原 英基| 岡部 伸幸| 横道 直佑| 高下 典子| 鍛治園 誠| 秋元 悠| 堀 圭介| 松原 稔| 那須 淳一郎| 谷本 光音| 木浦 勝行| 松岡 順治|
抄録  A 58-year-old man with cervical esophageal cancer and a history of epilepsy was treated with chemoradiotherapy from May of 2013. When tube feeding was initiated due to aspiration pneumonitis, the patient showed a degree of irritability that affected routine staff work and treatment compliance. We attempted to perform supportive care for maladjustment by the notice, the fast, and the tube feeding, but there was no improvement. After we added carbamazepine, primidone, and propericiazine (which had been canceled at the initiation of the tube feeding) to the patient's intravenous phenytoin, the symptoms and treatment compliance improved significantly. We concluded that the causes of the patient's irritability were maladjustment and his epilepsy.
キーワード てんかん(epilepsy) 易怒性(irritability) 適応障害(maladjustment)
出版物タイトル 岡山医学会雑誌
発行日 2014-08-01
126巻
2号
開始ページ 133
終了ページ 135
ISSN 0030-1558
言語 日本語
著作権者 Copyright (c) 2014 岡山医学会
論文のバージョン publisher
DOI 10.4044/joma.126.133
NAID 130004685264
タイトル(別表記) Molecular targeted therapy in myeloma and lymphoma
フルテキストURL 126_143.pdf
著者 佐伯 恭昌| 前田 嘉信| 谷本 光音|
キーワード 骨髄腫 リンパ腫 分子標的治療薬
出版物タイトル 岡山医学会雑誌
発行日 2014-08-01
126巻
2号
開始ページ 143
終了ページ 150
ISSN 0030-1558
言語 日本語
著作権者 Copyright (c) 2014 岡山医学会
論文のバージョン publisher
DOI 10.4044/joma.126.143
NAID 130004685266
著者 Iwatani, Kayoko| Takata, Katsuyoshi| Sato, Yasuharu| Miyata-Takata, Tomoko| Iwaki, Noriko| Cui, Wei| Sawada-Kitamura, Seiko| Sonobe, Hiroshi| Tamura, Maiko| Saito, Katsuhiko| Miyatani, Katsuya| Yamasaki, Rie| Yamadori, Ichiro| Fujii, Nobuharu| Terasaki, Yasushi| Maeda, Yoshinobu| Tanimoto, Mitsune| Nakamura, Naoya| Yoshino, Tadashi|
発行日 2014-07
出版物タイトル Human Pathology
45巻
7号
資料タイプ 学術雑誌論文
著者 海老沼 孝至| 曽我 賢彦| Sato, Takamaro| Matsunaga, Kazuyuki| Kudo, Chieko| Maeda, Hiroshi| 前田 嘉信| 谷本 光音| 髙柴 正悟|
発行日 2014-06
出版物タイトル Supportive Care in Cancer
22巻
6号
資料タイプ 学術雑誌論文
タイトル(別表記) Molecular targeted therapies in leukemia
フルテキストURL 126_49.pdf
著者 前田 嘉信| 谷本 光音|
キーワード 白血病 分子標的薬 チロシンキナーゼ阻害薬
出版物タイトル 岡山医学会雑誌
発行日 2014-04-01
126巻
1号
開始ページ 49
終了ページ 54
ISSN 0030-1558
関連URL http://www.okayama-u.ac.jp/user/oma/
言語 日本語
著作権者 Copyright (c) 2014 岡山医学会
論文のバージョン publisher
DOI 10.4044/joma.126.49
著者 Ochi, Nobuaki| Takigawa, Nagio| Harada, Daijiro| Yasugi, Masayuki| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2014-03-10
出版物タイトル Experimental Cell Research
322巻
1号
資料タイプ 学術雑誌論文
著者 Sugiyama, Haruko| Maeda, Yoshinobu| Nishimori, Hisakazu| Yamasuji, Yoshiko| Matsuoka, Ken-ichi| Fujii, Nobuharu| Kondo, Eisei| Shinagawa, Katsuji| Tanaka, Takehiro| Takeuchi, Kengo| Teshima, Takanori| Tanimoto, Mitsune|
発行日 2014-02
出版物タイトル Biology of Blood and Marrow Transplantation
20巻
2号
資料タイプ 学術雑誌論文
著者 Murakami, Toshi| Takigawa, Nagio| Ninomiya, Takashi| Ochi, Nobuaki| Yasugi, Masaaki| Honda, Yoshihiro| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tanimoto, Mitsune| Kiura, Katsuyuki|
発行日 2014-01
出版物タイトル Lung Cancer
83巻
1号
資料タイプ 学術雑誌論文